RASTETTER WILLIAM H 4

What Happened
William H. Rastetter, a director of Neurocrine Biosciences (NBIX), recorded an exercise/conversion of derivatives (code M) on 2026-05-21. The filing shows he acquired 3,318 shares at $0.00 and an equal disposition of 3,318 shares also recorded at $0.00. The reporting indicates these stem from Restricted Stock Units (RSUs) granted on 2025-05-21 that are fully vested (footnote F3). The filing reports no cash value for these transactions.

Key Details

• Transaction date: 2026-05-21. Price per share reported: $0.00. Shares acquired: 3,318; shares disposed: 3,318.
• Reported total cash value: $0.00 (per the Form 4 entries).
• Shares owned after transaction: The filing specifies at least 43,678 shares held by the Rastetter Family Trust (Reporting Person has voting and investment power) (footnote F1).
• Relevant footnotes: F2 explains each RSU converts to one share; F3 notes the RSU award was granted 5/21/2025 and is fully vested.
• Filing timeliness: The report was filed on 2026-05-21 for the 2026-05-21 transaction date (no late filing indicated).

Context
This is a derivative conversion of RSUs into common shares. The Form 4 records both the receipt and an equal disposition of 3,318 shares at $0.00; the filing does not state the reason for the disposition (e.g., sale, net settlement, or tax withholding). Such RSU conversions are common for insiders when awards vest and do not necessarily signal a buy/sell opinion about the stock.